Skip to main content
SpringerLink
Log in

Inflammation, Chronic Disease, and Cancer: Is Psychological Distress the Common Thread?

  • Chapter
  • First Online:
Psychological Aspects of Cancer

  • 2579 Accesses

Abstract

Mounting evidence suggests that the inflammatory mechanism plays a central role in the development and exacerbation of multiple chronic illnesses, including gastrointestinal, pulmonary, and cardiovascular disease, as well as obesity and rheumatoid arthritis. It has further been suggested that chronic inflammation is correlated with various types of cancer. While multiple studies have demonstrated that certain chronic diseases predict increased risk of malignancies, recent scholarship suggests that the inflammatory mechanism may in fact serve as a major factor in the pathogenesis of cancer. As psychological stress is known to influence individual levels of pro-inflammatory cytokines, it is possible that mental health problems such as chronic stress and depression may indirectly contribute to cancer development.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.

    CAS  PubMed  Google Scholar 

  2. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol. 2004;14:433–9.

    CAS  PubMed  Google Scholar 

  3. Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007;121(11):2373–80.

    CAS  PubMed  Google Scholar 

  4. Rakoff-Nahoum S. Why cancer and inflammation? Yale J Biol Med. 2006;79(3–4):123–30.

    CAS  PubMed  Google Scholar 

  5. Gulumian M. The role of oxidative stress in diseases caused by mineral dusts and fibres: current status and future of prophylaxis and treatment. Mol Cell Biochem. 1999;196:69–77.

    CAS  PubMed  Google Scholar 

  6. Ekbom A, Helmick C, Zack M, Adami H-O. Ulcerative colitis and colorectal cancer. N Engl J Med. 1990;323:1228–33.

    CAS  PubMed  Google Scholar 

  7. Mantovani A, Paola A, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.

    CAS  PubMed  Google Scholar 

  8. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315:1650–9.

    CAS  PubMed  Google Scholar 

  9. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441:431–6.

    CAS  PubMed  Google Scholar 

  10. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007;7: 41–51.

    CAS  PubMed  Google Scholar 

  11. Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A. 2003;100:2645–50.

    CAS  PubMed  Google Scholar 

  12. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, et al. IL-23 promotes tumour incidence and growth. Nature. 2006;442:461–5.

    CAS  PubMed  Google Scholar 

  13. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3(9):745–56.

    CAS  PubMed  Google Scholar 

  14. Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 2002;13(2): 135–41.

    CAS  PubMed  Google Scholar 

  15. Ariztia EV, Lee CJ, Gogoi R, Fishman DA. The tumor microenvironment: key to early detection. Crit Rev Clin Lab Sci. 2006;43:393–425.

    CAS  PubMed  Google Scholar 

  16. Negaard HF, Iversen N, Bowitz-Lothe IM, et al. Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. Leukemia. 2009;23(1):162–9.

    CAS  PubMed  Google Scholar 

  17. Kulbe H, Levinson NR, Balkwill F, Wilson JL. The chemokine network in cancer—much more than directing cell movement. Int J Dev Biol. 2004;48(5–6):489–96.

    CAS  PubMed  Google Scholar 

  18. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. The origin and function of tumor-associated macrophages. Immunol Today. 1992;13:265–70.

    CAS  PubMed  Google Scholar 

  19. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biocehem Pharmacol. 2006;72:1605–21.

    CAS  Google Scholar 

  20. Dantzer R, O’Connor J, Freund G, Johnson R, Kelley K. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46–57.

    CAS  PubMed  Google Scholar 

  21. Quan N, Banks WA. Brain-immune communication pathways. Brain Behav Immun. 2007;21(6):727–35.

    CAS  PubMed  Google Scholar 

  22. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997;349(9063): 1436–42.

    CAS  PubMed  Google Scholar 

  23. Steptoe A, Hamer M, Chida Y. The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis. Brain Behav Immun. 2007;21(7):901–12.

    CAS  PubMed  Google Scholar 

  24. Leonard BE. The concept of depression as a dysfunction of the immune system. Curr Immunol Rev. 2010;6(3):205–12.

    CAS  PubMed  Google Scholar 

  25. Godbout JP, Berg BM, Krzyszton C, Johnson RW. Alpha-tocopherol attenuates NFkappaB activation and pro-inflammatory cytokine production in brain and improves recovery from lipopolysaccharide-induced sickness behavior. J Neuroimmunol. 2005;169(1–2):97–105.

    CAS  PubMed  Google Scholar 

  26. Heyen JR, Ye S, Finck BN, Johnson RW. Interleukin (IL)-10 inhibits IL-6 production in microglia by preventing activation of NF-kappaB. Brain Res Mol Brain Res. 2000;77(1):138–47.

    CAS  PubMed  Google Scholar 

  27. Stewart JC, Rand KL, Muldoon MF, Kamarck TW. A prospective evaluation of the directionality of the depression-inflammation relationship. Brain Behav Immun. 2009;23(7):936–44.

    CAS  PubMed  Google Scholar 

  28. Brown KD, Claudio E, Siebenlist U. The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther. 2008; 10(4):212.

    PubMed  Google Scholar 

  29. Amos N, Lauder S, Evans A, Feldmann M, Bondeson J. Adenoviral gene transfer into osteoarthritis synovial cells using the endogenous inhibitor Ikappa B alpha reveals that most, but not all, inflammatory and destructive mediators are NF-kappa B dependent. Rheumatology. 2006;45:1201–9.

    CAS  PubMed  Google Scholar 

  30. Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis. 2000;59:121–7.

    Google Scholar 

  31. Guerne PA, Zuraw BL, Vaughan JH, Carson DA, Lotz M. Synovium as a source of interleukin 6 in vitro: contribution to local and systemic manifestations of arthritis. J Clin Invest. 1989;83:585–92.

    CAS  PubMed  Google Scholar 

  32. Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993;52:232–4.

    CAS  PubMed  Google Scholar 

  33. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. Br Med J. 1998;317:180–1.

    CAS  Google Scholar 

  34. Baeklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54(3):692–701.

    Google Scholar 

  35. Jones M, Symmons D, Finn J, et al. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol. 1996;35:738–45.

    CAS  PubMed  Google Scholar 

  36. Asten P, Barrett J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol. 1999;26:1705–14.

    CAS  PubMed  Google Scholar 

  37. van de Rijn M, Cleary M, Variakojis D, et al. Epstein-Barr virus clonality in lymphomas occurring in patients with rheumatoid arthritis. Arthritis Rheum. 1996;39:638–42.

    PubMed  Google Scholar 

  38. Dawson T, Starkbaum G, Wood B, et al. Epstein-Barr virus, methotrexate, and lymphoma in patients with rheumatoid arthritis and primary Sjogren’s syndrome: case series. J Rheumatol. 2001;28:47–53.

    CAS  PubMed  Google Scholar 

  39. Wolfe F. Inflammatory activity, but not methotrexate or prednisone use predicts non-Hodgkins lymphoma in rheumatoid arthritis: a 25-year study of 1,767 RA patients. Arthritis Rheum. 1998;41:S188.

    Google Scholar 

  40. Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10(2):R45.

    PubMed  Google Scholar 

  41. Bachen EA, Chesney MA, Criswell LA. Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. Arthritis Rheum. 2009; 61(6):822–9.

    PubMed  Google Scholar 

  42. Seguí J, Ramos-Casals M, García-Carrasco M, et al. Psychiatric and psychosocial disorders in patients with systemic lupus erythematosus: a longitudinal study of active and inactive stages of the disease. Lupus. 2000;9(8):584–8.

    PubMed  Google Scholar 

  43. Waterloo K, Omdal R, Husby G, Mellgren SI. Emotional status in systemic lupus erythematosus. Scand J Rheumatol. 1998;27(6):410–4.

    CAS  PubMed  Google Scholar 

  44. Nery FG, Borba EF, Viana VS, et al. Prevalence of depressive and anxiety disorders in systemic lupus erythematosus and their association with anti-ribosomal P antibodies. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(3):695–700.

    CAS  PubMed  Google Scholar 

  45. Mella LF, Bértolo MB, Dalgalarrondo P. Depressive symptoms in rheumatoid arthritis. Rev Bras Psiquiatr. 2010;32(3):257–63.

    PubMed  Google Scholar 

  46. Davis MC, Zautra AJ, Younger J, Motivala SJ, Attrep J, Irwin MR. Chronic stress and regulation of cellular markers of inflammation in rheumatoid arthritis: implications for fatigue. Brain Behav Immun. 2008;22(1):24–32.

    CAS  PubMed  Google Scholar 

  47. Carney RM, Freedland KE, Miller GE, Jaffe AS. Depression as a risk factor for cardiac mortality and morbidity: a review of potential mechanisms. J Psychosom Res. 2002;53(4):897–902.

    PubMed  Google Scholar 

  48. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27(1):24–31.

    CAS  PubMed  Google Scholar 

  49. Miller GE, Stetler CA, Carney RM, Freedland KE, Banks WA. Clinical depression and inflammatory risk markers for coronary heart disease. Am J Cardiol. 2002;90(12):1279–83.

    PubMed  Google Scholar 

  50. Miller GE, Freedland KE, Carney RM, Stetler CA, Banks WA. Pathways linking depression, adiposity, and inflammatory markers in healthy young adults. Brain Behav Immun. 2003;17(4):276–85.

    CAS  PubMed  Google Scholar 

  51. Low CA, Cunningham AL, Kao AH, Krishnaswami S, Kuller LH, Wasko MC. Association between C-reactive protein and depressive symptoms in women with rheumatoid arthritis. Biol Psychol. 2009;81(2): 131–4.

    PubMed  Google Scholar 

  52. Carr, FN, Nicassio, PM, Ishimori, ML, Moldovan, I, Katsaros, E, Torralba, K. Depression predicts patient-reported fatigue in systemic lupus erythematosus (SLE). In: Society for Behavioral Medicine Annual Meeting. Washington, DC; April 2011.

    Google Scholar 

  53. Bruce TO. Comorbid depression in rheumatoid arthritis: pathophysiology and clinical implications. Curr Psychiatry Rep. 2008;10(3):258–64.

    PubMed  Google Scholar 

  54. Kiebles JL, Doerfler B, Keefer L. Preliminary evidence supporting a framework of psychological adjustment to inflammatory bowel disease. Inflamm Bowel Dis. 2010;16(10):1685–95.

    PubMed  Google Scholar 

  55. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126(2): 451–9.

    PubMed  Google Scholar 

  56. Itzkowitz SH, Yio X. Inflammation and Cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004;287(1):G7–17.

    CAS  PubMed  Google Scholar 

  57. Mitsuyama K, Matsumoto S, Rose-John S, et al. STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut. 2006;55:1263–9.

    CAS  PubMed  Google Scholar 

  58. Becker C, Fantini MC, Schramm C, et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity. 2004;21:491–501.

    CAS  PubMed  Google Scholar 

  59. Braegger CP, Nicholls S, Murch SH, Steohens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet. 1992;339(8785):89–91.

    CAS  PubMed  Google Scholar 

  60. Theiss AL, Jenkins AK, Okoro NI, Klapproth JMA, Merlin D, Sitaraman SV. Prohibitin inhibits tumor necrosis factor alpha-induced nuclear factor-kappa b nuclear translocation via the novel mechanism of decreasing importin-α3 expression. Mol Biol Cell. 2009;20(20):4412–23.

    CAS  PubMed  Google Scholar 

  61. Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, et al. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor NFKB1, and peroxisome proliferator-activated receptor with colorectal cancer. Cancer Res. 2003;63(13):3560–6.

    CAS  PubMed  Google Scholar 

  62. Jayaram H, Satsangi J, Chapman RW. Increased colorectal neoplasia in chronic ulcerative colitis complicated by primary sclerosing cholangitis: fact or fiction? Gut. 2001;48:430–4.

    CAS  PubMed  Google Scholar 

  63. Shetty K, Rybicki L, Brzezinski A, Carey WD, Lashner BA. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol. 1999;94(6):1643–9.

    CAS  PubMed  Google Scholar 

  64. Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol. 1997;39:1–20.

    CAS  PubMed  Google Scholar 

  65. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer. 2003;276:276–85.

    Google Scholar 

  66. Farrokhyar F, Marshall JK, Easterbrook B, Irvine EJ. Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm Bowel Dis. 2006;12(1):38–46.

    PubMed  Google Scholar 

  67. Kovács Z, Kovács F. Depressive and anxiety symptoms, dysfunctional attitudes and social aspects in irritable bowel syndrome and inflammatory bowel disease. Int J Psychiatry Med. 2007;37(3):245–55.

    PubMed  Google Scholar 

  68. Maunder RG, Levenstein S. The role of stress in the development and clinical course of inflammatory bowel disease: epidemiological evidence. Curr Mol Med. 2008;8(4):247–52.

    CAS  PubMed  Google Scholar 

  69. Cámara RJ, Schoepfer AM, Pittet V, Begré S, von Känel R; the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS) Group. Mood and nonmood components of perceived stress and exacerbation of crohn’s disease. Inflamm Bowel Dis. 2011. doi:10.1002/ibd.21623.

  70. Raison CL, Lowry CA, Rook GA. Inflammation, sanitation, and consternation: loss of contact with coevolved, tolerogenic microorganisms and the pathophysiology and treatment of major depression. Arch Gen Psychiatry. 2010;67(12):1211–24.

    CAS  PubMed  Google Scholar 

  71. Rao AV, Bested AC, Beaulne TM, et al. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog. 2009;1(1):6.

    PubMed  Google Scholar 

  72. Rini C, Jandorf L, Valdimarsdottir H, Brown K, Itzkowitz SH. Distress among inflammatory bowel disease patients at high risk for colorectal cancer: a preliminary investigation of the effects of family history of cancer, disease duration, and perceived social support. Psychooncology. 2008;17(4):354–62.

    PubMed  Google Scholar 

  73. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA. 2002;288:1723–7.

    PubMed  Google Scholar 

  74. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–16.

    PubMed  Google Scholar 

  75. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 2002;156:1070–7.

    PubMed  Google Scholar 

  76. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007;132(6):2169–80.

    CAS  PubMed  Google Scholar 

  77. Festa A, D’Agostino Jr R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation. 2000;102:42–7.

    CAS  PubMed  Google Scholar 

  78. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 1998;41:1241–8.

    CAS  PubMed  Google Scholar 

  79. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001;280:E745–51.

    CAS  PubMed  Google Scholar 

  80. Rajala MW, Sherer PE. Minireview: the adipocyte—at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology. 2003;144:3765–73.

    CAS  PubMed  Google Scholar 

  81. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 2004;145:2273–82.

    CAS  PubMed  Google Scholar 

  82. Bilan PJ, Samokhvalov V, Koshkina A, Schertzer JD, Samaan MC, Klip A. Direct and macrophage-mediated actions of fatty acids causing insulin resistance in muscle cells. Arch Physiol Biochem. 2009;115: 176–90.

    CAS  PubMed  Google Scholar 

  83. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860–7.

    CAS  PubMed  Google Scholar 

  84. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995;95:2409–15.

    CAS  PubMed  Google Scholar 

  85. Fernandez-Real JM, Pickup JC. Innate immunity, insulin resistance and type 2 diabetes. Trends Endocrinol Metab. 2008;19:10–6.

    CAS  PubMed  Google Scholar 

  86. Panagiotakos DB, Pitsavos C, Yannakoulia M, Chrysohoou C, Stefanadis C. The implication of obesity and central fat on markers of chronic inflammation: the attica study. Artherosclerosis. 2005;183:308–15.

    CAS  Google Scholar 

  87. Solinas G, Naugler W, Galimi F, Lee MS, Karin M. Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates. Proc Natl Acad Sci U S A. 2006;103:16454–9.

    CAS  PubMed  Google Scholar 

  88. Lamb RE, Goldstein BJ. Modulating an oxidative-inflammatory cascade: potential new treatment strategy for improving glucose metabolism, insulin resistance, and vascular function. Int J Clin Pract. 2008;62:1087–95.

    CAS  PubMed  Google Scholar 

  89. West IC. Radicals and oxidative stress in diabetes. Diabet Med. 2000;17:171–80.

    CAS  PubMed  Google Scholar 

  90. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106:2067–72.

    CAS  PubMed  Google Scholar 

  91. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002;23:599–622.

    CAS  PubMed  Google Scholar 

  92. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002;3:565–74.

    PubMed  Google Scholar 

  93. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579–91.

    CAS  PubMed  Google Scholar 

  94. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38.

    PubMed  Google Scholar 

  95. Park EJ, Lee JH, Yu GY, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140(2):197–208.

    CAS  PubMed  Google Scholar 

  96. de Wit LM, van Straten A, van Herten M, Penninx BW, Cuijpers P. Depression and body mass index, a u-shaped association. BMC Public Health. 2009;9:14.

    PubMed  Google Scholar 

  97. Faith MS, Matz PE, Jorge MA. Obesity-depression associations in the population. J Psychosom Res. 2002;53(4):935–42.

    PubMed  Google Scholar 

  98. Scott KM, McGee MA, Wells JE, Oakley Browne MA. Obesity and mental disorders in the adult general population. J Psychosom Res. 2008;64(1):97–105.

    PubMed  Google Scholar 

  99. Penninx BW, Beekman AT, Honig A, et al. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry. 2001;58(3):221–7.

    CAS  PubMed  Google Scholar 

  100. Keddie AM. Associations between severe obesity and depression: results from the National Health and Nutrition Examination Survey, 2005–2006. Prev Chronic Dis. 2011;8(3). http://www.cdc.gov/pcd/issues/2011/may/10_0151.htm. Accessed 10 May 2011.

  101. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67(3):220–9.

    PubMed  Google Scholar 

  102. Taylor VH, MacQueen GM. The role of adipokines in understanding the associations between obesity and depression. J Obes. 2010. doi:10.1155/2010/748048

  103. Talley NJ. Definitions, epidemiology, and impact of chronic constipation. Rev Gastroenterol Disord. 2004;4 Suppl 2:S3–10.

    PubMed  Google Scholar 

  104. John BJ, Abulafi AM, Poullis A, Mendall MA. Chronic subclinical bowel inflammation may explain increased risk of colorectal cancer in obese people. Gut. 2007;56(7):1034–5.

    PubMed  Google Scholar 

  105. Barbu C, Iordache M, Man MG. Inflammation in COPD: pathogenesis, local and systemic effects. Rom J Morphol Embryol. 2011;52(1):21–7.

    PubMed  Google Scholar 

  106. Schunemann HJ, Dorn J, Grant BJ, et al. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest. 2000;118:656–64.

    CAS  PubMed  Google Scholar 

  107. Bang KM, Gergen PJ, Kramer R, et al. The effect of pulmonary impairment on all-cause mortality in a national cohort. Chest. 1993;103:536–40.

    CAS  PubMed  Google Scholar 

  108. Engstrom G, Lind P, Hedblad B, et al. Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins. Circulation. 2002;106(20):2555–60.

    CAS  PubMed  Google Scholar 

  109. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115–26.

    CAS  PubMed  Google Scholar 

  110. Hashimoto H, Kitagawa K, Hougaku H, et al. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation. 2001;104(1):63–7.

    CAS  PubMed  Google Scholar 

  111. Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;99:237–42.

    CAS  PubMed  Google Scholar 

  112. Sin DD, Man SF. Systemic inflammation and mortality in chronic obstructive pulmonary disease. Can J Physiol Pharmacol. 2007;85:141–7.

    CAS  PubMed  Google Scholar 

  113. Mannino DM. Epidemiology and global impact of chronic obstructive pulmonary disease. Semin Respir Crit Care Med. 2005;26:204–10.

    PubMed  Google Scholar 

  114. Punturieri A, Szabo E, Croxton TL, Shapiro SD, Dubinett SM. Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. J Natl Cancer Inst. 2009;101:554–9.

    PubMed  Google Scholar 

  115. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645–53.

    CAS  PubMed  Google Scholar 

  116. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004;364:709–21.

    PubMed  Google Scholar 

  117. O’Donnell RA, Richter A, Ward J, et al. Expression of ErbB receptors and mucins in the airways of long-term current smokers. Thorax. 2004;59:1032–40.

    PubMed  Google Scholar 

  118. Kurie JM, Shin HJ, Lee JS, et al. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res. 1996;2: 1787–93.

    CAS  PubMed  Google Scholar 

  119. Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn Jr PA. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol. 2002;29:3–14.

    CAS  PubMed  Google Scholar 

  120. Karin M. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol. 2009;1(5):a000141.

    PubMed  Google Scholar 

  121. Hayashi Y, Senjyu H, Iguchi A, et al. Prevalence of depressive symptoms in Japanese male patients with chronic obstructive pulmonary disease. Psychiatry Clin Neurosci. 2011;65(1):82–8.

    PubMed  Google Scholar 

  122. Al-shair K, Kolsum U, Dockry R, Morris J, Singh D, Vestbo J. Biomarkers of systemic inflammation and depression and fatigue in moderate clinically stable COPD. Respir Res. 2011;12:3.

    PubMed  Google Scholar 

  123. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5): 1165–85.

    CAS  PubMed  Google Scholar 

  124. Al-Herz A, Ensworth S, Shojania K, Esdaile JM. Cardiovascular risk factor screening in systemic lupus erythematosus. J Rheumatol. 2003;30(3): 493–6.

    PubMed  Google Scholar 

  125. Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus. 2000;9(3):170–5.

    CAS  PubMed  Google Scholar 

  126. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology. 2003;144(6):2195–200.

    CAS  PubMed  Google Scholar 

  127. Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens. 2005;19(2):149–54.

    CAS  PubMed  Google Scholar 

  128. Vázquez-Oliva G, Fernández-Real JM, Zamora A, Vilaseca M, Badimón L. Lowering of blood pressure leads to decreased circulating interleukin-6 in hypertensive subjects. J Hum Hypertens. 2005;19(6): 457–62.

    PubMed  Google Scholar 

  129. Frasure-Smith N, Lespérance F, Irwin MR, Talajic M, Pollock BG. The relationships among heart rate variability, inflammatory markers and depression in coronary heart disease patients. Brain Behav Immun. 2009;23(8):1140–7.

    CAS  PubMed  Google Scholar 

  130. Dyer AR, Stamler J, Berkson DM, Lindberg HA, Stevens E. High blood-pressure: a risk factor for cancer mortality? Lancet. 1975;1:1051–6.

    CAS  PubMed  Google Scholar 

  131. Raynor Jr WR, Shekelle RB, Rossof AH, Maliza C, Paul O. High blood pressure and 17-year cancer mortality in the Western Electric Health Study. Am J Epidemiol. 1981;113:371–7.

    PubMed  Google Scholar 

  132. Buck C, Donner A. Cancer incidence in hypertensives. Cancer. 1987;59:1386–90.

    CAS  PubMed  Google Scholar 

  133. Chow WH, Gridley G, Fraumeni JF, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med. 2000;343:1305–11.

    CAS  PubMed  Google Scholar 

  134. Grossman E, Messerli FH, Boyko V, Goldbourt U. Is there an association between hypertension and cancer mortality? Am J Med. 2002;112:479–86.

    PubMed  Google Scholar 

  135. Ohira T. Psychological distress and cardiovascular disease: the Circulatory Risk in Communities Study (CIRCS). J Epidemiol. 2010;20(3):185–91.

    PubMed  Google Scholar 

  136. Malan L, Schutte AE, Malan NT, et al. Specific coping strategies of Africans during urbanization: comparing cardiovascular responses and perception of health data. Biol Psychol. 2006;72(3):305–10.

    PubMed  Google Scholar 

  137. Reid JL, Morton DJ, Wingard DL, Garrett MD, von Muhlen D, Slymen D. Obesity and other cardiovascular disease risk factors and their association with osteoarthritis in Southern California American Indians, 2002–2006. Ethn Dis. 2010;20(4):416–22.

    PubMed  Google Scholar 

  138. Heard E, Whitfield KE, Edwards CL, Bruce MA, Beech BM. Mediating effects of social support on the relationship among perceived stress, depression, and hypertension in African Americans. J Natl Med Assoc. 2011;103(2):116–22.

    PubMed  Google Scholar 

  139. Mashele N, Van Rooyen JM, Malan L, Potgieter JC. Cardiovascular function and psychological distress in urbanised black South Africans: the SABPA study. Cardiovasc J Afr. 2010;21(4):206–11.

    CAS  PubMed  Google Scholar 

  140. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics–2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18–209.

    PubMed  Google Scholar 

  141. Albert CM, Ma J, Rifai N, et al. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation. 2002;105:2595–9.

    CAS  PubMed  Google Scholar 

  142. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factors. Circulation. 2004;109:II2–110.

    PubMed  Google Scholar 

  143. Libby P, Ridker PM. Novel inflammatory markers of coronary risk. Theory versus practice. Circulation. 1999;100:1148–50.

    CAS  PubMed  Google Scholar 

  144. Amer MS, Elawam AE, Khater MS, Omar OH, Mabrouk RA, Taha HM. Association of high-sensitivity C-reactive protein with carotid artery intima-media thickness in hypertensive older adults. J Am Soc Hypertens. 2011;5(5):395–400.

    CAS  PubMed  Google Scholar 

  145. Little PJ, Chait A, Bobik A. Cellular and cytokine-based inflammatory processes as novel therapeutic targets for the prevention and treatment of atherosclerosis. Pharmacol Ther. 2011;131(3):255–68.

    CAS  PubMed  Google Scholar 

  146. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and risks of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–9.

    CAS  PubMed  Google Scholar 

  147. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007–11.

    CAS  PubMed  Google Scholar 

  148. Pasceri P, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102: 2165–8.

    CAS  PubMed  Google Scholar 

  149. Sakkinen P, Abbott RD, Curb JD, et al. C-reactive protein and myocardial infarction. J Clin Epidemiol. 2002;55:445–51.

    PubMed  Google Scholar 

  150. Willerson JT. Systemic and local inflammation in patients with unstable atherosclerotic plaques. Prog Cardiovasc Dis. 2002;44:469–78.

    CAS  PubMed  Google Scholar 

  151. Frasure-Smith N, Lespérance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA. 1993;270(15):1819–25.

    CAS  PubMed  Google Scholar 

  152. Welin C, Lappas G, Wilhelmsen L. Independent importance of psychosocial factors for prognosis after myocardial infarction. J Intern Med. 2000;247(6):629–39.

    CAS  PubMed  Google Scholar 

  153. Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med. 2004;66(6):802–13.

    PubMed  Google Scholar 

  154. Rugulies R. Depression as a predictor for coronary heart disease. a review and meta-analysis. Am J Prev Med. 2002;23(1):51–61.

    PubMed  Google Scholar 

  155. Appels A, Bär FW, Bär J, Bruggeman C, de Baets M. Inflammation, depressive symptomtology, and coronary artery disease. Psychosom Med. 2000;62(5):601–5.

    CAS  PubMed  Google Scholar 

  156. Norman GJ, Zhang N, Morris JS, Karelina K, Berntson GG, DeVries AC. Social interaction modulates autonomic, inflammatory, and depressive-like responses to cardiac arrest and cardiopulmonary resuscitation. Proc Natl Acad Sci U S A. 2010;107(37):16342–7.

    CAS  PubMed  Google Scholar 

  157. Thornton LM, Andersen BL, Schuler TA, Carson 3rd WE. A psychological intervention reduces inflammatory markers by alleviating depressive symptoms: secondary analysis of a randomized controlled trial. Psychosom Med. 2009;71(7):715–24.

    CAS  PubMed  Google Scholar 

  158. Doering LV, Cross R, Vredevoe D, Martinez-Maza O, Cowan MJ. Infection, depression, and immunity in women after coronary artery bypass: a pilot study of cognitive behavioral therapy. Altern Ther Health Med. 2007;13(3):18–21.

    PubMed  Google Scholar 

  159. Yu B, Becnel J, Zerfaoui M, Rohatgi R, Boulares AH, Nichols CD. Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency. J Pharmacol Exp Ther. 2008;327(2):316–23.

    CAS  PubMed  Google Scholar 

  160. Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl). 2003;170(4):429–33.

    CAS  Google Scholar 

  161. Basterzi AD, Aydemir C, Kisa C, et al. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum Psychopharmacol. 2005;20(7):473–6.

    CAS  PubMed  Google Scholar 

  162. Leo R, Di Lorenzo G, Tesauro M, et al. Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy. J Clin Psychiatry. 2006;67(11):1760–6.

    CAS  PubMed  Google Scholar 

  163. Kubera M, Maes M, Kenis G, Kim YK, Lasoń W. Effects of serotonin and serotonergic agonists and antagonists on the production of tumor necrosis factor alpha and interleukin-6. Psychiatry Res. 2005; 134(3):251–8.

    CAS  PubMed  Google Scholar 

  164. Smedley BD, Stith AY, Nelson AR. Unequal treatment: confronting racial and ethnic disparities in health care. Washington, DC: The National Academies Press; 2002.

    Google Scholar 

  165. Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004;54(2):78–93.

    PubMed  Google Scholar 

  166. Roberts CB, Vines AI, Kaufman JS, James SA. Cross-sectional association between perceived discrimination and hypertension in African-American men and women: the pitt county study. Am J Epidemiol. 2008;167:624–32.

    PubMed  Google Scholar 

  167. Lewis TT, Barnes LL, Bienias JL, Lackland DT, Evans DA, Mendes de Leon CF. Perceived discrimination and blood pressure in older African American and White adults. J Gerontol A Biol Sci Med Sci. 2009;64A:1002–8.

    Google Scholar 

  168. Lewis TT, Aiello AE, Leurgans S, Kelly J, Barnes LL. Self-reported experiences of everyday discrimination are associated with elevated C-reactive protein levels in older African-American adults. Brain Behav Immun. 2010;24(3):438–43.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Psychology, California School of Professional Psychology at Alliant International University—Los Angeles, 1000S. Fremont Ave, Unit #5, Alhambra, CA, 91803, USA

    Feridey N. Carr Ph.D. & Elizabeth M. Sosa M.A.

Authors
  1. Feridey N. Carr Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elizabeth M. Sosa M.A.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Feridey N. Carr Ph.D. .

Editor information

Editors and Affiliations

  1. Kimmel Cancer Center, Thomas Jefferson University, S. 10th Street 233, Philadelphia, 19107, Pennsylvania, USA

    Brian I. Carr

  2. STARZL TRANSPLAN INST, University of Pittsburgh, 5TH AVE 7 MONTEFIORE 3459, PITTSBURGH, 15213, Pennsylvania, USA

    JENNIFER STEEL

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Carr, F.N., Sosa, E.M. (2013). Inflammation, Chronic Disease, and Cancer: Is Psychological Distress the Common Thread?. In: Carr, B., STEEL, J. (eds) Psychological Aspects of Cancer. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-4866-2_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-4866-2_2

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4614-4865-5

  • Online ISBN: 978-1-4614-4866-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation